Has Rebecca Cline received payments from drug or device companies?

Yes. Drug and device makers reported $2,987 in general payments to Rebecca Cline across 152 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Rebecca Cline did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Rebecca Cline come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Rebecca Cline

Psychiatric/Mental Health · Tulsa, OKNPI 1366720229

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 97.4% of the total across 152 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 17 manufacturers, the largest accounting for just 19.6% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2021 at $1,834 and has fallen 93.7% since, to $115 in 2024.

$2,987in general payments, 2019–2025

Across 152 payments — averaging $19.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Otsuka America Pharmaceutical, Inc.$584
Johnson & Johnson$375
Takeda Pharmaceuticals U.S.A., Inc.$345
AbbVie$253
Alkermes, Inc.$250
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$217
plus $962 from 11 others

What the payments were for

Food & beverage$2,91097%
Education$773%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Otsuka America Pharmaceutical, Inc.	36	$584
Johnson & Johnson	13	$375
Takeda Pharmaceuticals U.S.A., Inc.	25	$345
AbbVie(2 entities)	20	$253
Alkermes, Inc.	4	$250
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)	14	$217
Teva Pharmaceuticals USA, Inc.	6	$205
Lundbeck LLC	10	$133
Neurocrine Biosciences, Inc.	1	$124
Axsome Therapeutics, Inc.	1	$118
Vanda Pharmaceuticals Inc.	6	$110
Ironshore Pharmaceuticals Inc.	5	$98
Supernus Pharmaceuticals, Inc.	5	$87
Avanir Pharmaceuticals, Inc.	2	$29
Almatica Pharma LLC	2	$27
Sunovion Pharmaceuticals Inc.	1	$19
Eisai Inc.	1	$13

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,987 in reported general payments places this provider in the 75th percentile of 231 psychiatric/mental health providers in Oklahoma.

See all psychiatric/mental health providers in Oklahoma →

Medicare billing

Part B allowed, 2024

$10,475

Medicare patients

Services billed

116

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
TrintellixVortioxetine Hydrobromide	13	$6,531
Atomoxetine Hcl	23	$1,796
Quetiapine Fumarate	17	$588
Desvenlafaxine Succinate ErDesvenlafaxine Succinate	18	$467
Duloxetine Hcl	21	$328
Prazosin Hcl	29	$299
Trazodone Hcl	50	$270
Lamotrigine	38	$229
Mirtazapine	19	$211
Venlafaxine Hcl ErVenlafaxine Hcl	24	$186
Bupropion XlBupropion Hcl	17	$179
Sertraline Hcl	15	$174
Propranolol Hcl	19	$166

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

Company	Paid to this provider	Part D cost of their drugs
Takeda Pharmaceuticals U.S.A., Inc.Trintellix	$345	$6,53113 claims
Almatica Pharma LLCSertraline Hcl	$27	$17415 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 231 psychiatric/mental health providers in Oklahoma.

Other psychiatric/mental health in Tulsa

See the full list for Oklahoma →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →